Funder
Novo Nordisk
Department of mechanical engineering, MIT Brigham and woman's hospital division of gastroenterology
National Science Foundation
MIT undergraduate research opportunities program
Foundation for the National Institutes of Health
Olof Viking Bjork scholarship trust
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference35 articles.
1. Turner, R. C., Cull, C. A., Frighi, V. & Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J. Am. Med. Assoc. 281, 2005–2012 (1999).
2. Pratley, R. E. et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456 (2010).
3. Korytkowski, M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. 26, S18–S24 (2002).
4. Boye, K. S. et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Heal. Econ. 12, 219–230 (2011).
5. Calvert, M. J., McManus, R. J. & Freemantle, N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br. J. Gen. Pract. 57, 455–460 (2007).
Cited by
189 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献